CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Brand Name||Stivarga Resubmission (CRC)|
|Indication||Metastatic Colorectal Cancer|
|Funding Request||Treatment of patients with metastatic colorectal cancer (CRC), and an ECOG status of ≤1, who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy|
|Pre Noc Submission||No|
|NOC Date||March 11, 2013|
|Submission Date||December 19, 2014|
|Submission Deemed Complete||January 12, 2015|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||January 12, 2015|
|Check-point meeting||March 2, 2015|
|pERC Meeting||April 17, 2015|
|Initial Recommendation Issued||April 30, 2015|
|Clarification||Please note that the April pERC meeting was conducted over two days. The original date for the posting of pERC Initial Recommendation remained as April 30, 2015.|
|Feedback Deadline ‡||May 14, 2015|
|pERC Reconsideration Meeting||July 2, 2015|
|Clarification||Due to the number of items for deliberation, the pERC meeting was conducted over two days. Unable to reach quorum for either day around the target reconsideration meeting date of June 18, 2015, pERC held deliberations for all reconsideration items, including the regorafenib resubmission, on July 2, 2015|
|Final Recommendation Issued||July 16, 2015|
|Notification to Implement Issued||July 31, 2015|
|Therapeutic Area||Metastatic Colorectal Cancer|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.